UGCG and Fabry disease: Venglustat, another SRT drug, also inhibits glucosylceramide synthase and has shown potential in phase two trials for Anderson–Fabry disease (NCT02228460), with ongoing studies assessing its long-term efficacy and safety (NCT02489344).